Magnesium Claims for BP; S3 Ultra’s Higher Gradients; Antiplatelets Flop in COVID

Participants in the Framingham Study showed an increased lifetime risk of heart failure from 1965-1989 to 1990-2014. (Journal of the American College of Cardiology)

A history of recent COVID-19 may warrant additional preoperative cardiac assessment prior to noncardiac surgery for some patients, but the evidence is lacking. (JAMA Surgery)

FDA announced that it is on board with companies making certain health claims regarding magnesium consumption and a reduced risk of hypertension.

Early studies probed coronary alignment during transcatheter aortic valve replacement (TAVR) to preserve coronary access in some patients. (JACC: Cardiovascular Interventions)

Compared with the Sapien 3, the newer-generation Sapien 3 Ultra transcatheter heart valve was associated with higher postprocedural gradients but no difference in 30-day clinical outcomes in a German registry. (Heart)

What even counts as optimal medical therapy (OMT) for stable ischemia? And how does one know when OMT for symptom relief has supposedly failed? (The Lancet)

In a cohort of Medicare beneficiaries with heart failure with reduced ejection fraction, those on cardiac resynchronization therapy with defibrillators had better outcomes than peers with implantable cardioverter-defibrillators alone. (JACC: Heart Failure)

Adding a P2Y12 inhibitor to a therapeutic dose of heparin was no help for survival or heart and lung function in people hospitalized with COVID-19. (JAMA)

The incidence of thrombosis with thrombocytopenia syndrome after mRNA COVID-19 vaccination was just 0.00855 per million doses, according to surveillance on the Vaccine Adverse Event Reporting System. (Annals of Internal Medicine)

Teenagers with greater arterial stiffness were more likely to develop insulin resistance and dyslipidemia in young adulthood. (Hypertension)

In the POINT trial, stroke patients with an infarct visible on imaging seemed to benefit more from clopidogrel-aspirin therapy for the prevention of recurrent ischemic events. (JAMA Neurology)

Daiichi Sankyo sold U.S. sales and distribution rights to eight cardiovascular drugs, including olmesartan (Benicar) and prasugrel (Effient), in its pivot to a greater emphasis on oncology. (FiercePharma)

Antisense oligonucleotide therapy with olezarsen reduced triglycerides, apolipoprotein C-III, very low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B in a small phase II trial of people at high risk for cardiovascular disease. (European Heart Journal)

A mouse study suggested a therapeutic target for heart failure and dilated cardiomyopathy in myocardial metabolism clock signaling. (Circulation)

Premature retinal aging may be a novel marker of cardiovascular risk, according to a preprint on medRxiv.

The parents of late “Jeopardy” contestant Brayden Smith are suing Nevada doctors and nurses for failing to give their son anticoagulation during colon removal surgery. He died from blood clots in his lungs several weeks after the surgery, at the age of 24. (People)

Soccer players Pierre-Emerick Aubameyang of Gabon and Alphonso Davies of Canada were pulled from rotation because of heart irregularities detected after recent COVID infections. (The Guardian)